

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

WORLD HEALTH ORGANIZATION
TECHNICAL REPORT SERIES

No. 361

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Nineteenth Report

WORLD HEALTH ORGANIZATION

GENEVA

1967

© World Health Organization 1967

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization.

For rights of reproduction or translation of WHO publications *in toto*, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature which are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

CONTENTS

	Page
GENERAL	7
PHARMACOLOGICAL	
Antibiotics	
1. Gramicidin	8
2. Dihydrostreptomycin	8
3. Viomycin	8
4. Paromomycin	9
5. Oxytetracycline	9
6. Cefalotin	9
7. Lincomycin	10
8. Chlortetracycline	10
9. Hygromycin B	10
10. Tylosin	10
11. Rifamycin SV	11
12. Colistin	11
13. Colistin methane sulfonate	11
14. Procaine benzylpenicillin in oil with aluminium monostearate	11
15. Olivomycin	12
16. Gentamycin	12
17. Other antibiotics	12
Hormones and Enzymes	
18. Human growth hormone	12
19. Growth hormone	13
20. Heparins	13
21. Urokinase	13
22. Other components of the blood coagulation and fibrinolytic systems	13
23. Human insulin	14
24. Human thyrotrophin	14
25. Serum gonadotrophin	14
26. Parathyroid hormone	15
27. Calcitonin	15
28. Gastrin	15
29. Glucagon	15

	Page
IMMUNOLOGICAL	
Antigens	
30. Anthrax vaccine	16
31. BCG vaccine	16
32. Old tuberculin	16
33. Other tuberculins	17
34. Rabies vaccine	17
35. Typhoid vaccine	18
36. Cholera vaccine	18
37. Tetanus toxoid (adsorbed)	18
38. <i>Clostridium oedematiens</i> (alpha) toxoid	19
39. Measles vaccine (inactivated)	19
40. Influenza virus haemagglutinin	19
41. Cardioliipin	19
42. Rinderpest vaccine	20
Antibodies	
43. Anti- <i>Brucella abortus</i> serum	20
44. Tetanus antitoxin	20
45. Anti-Newcastle-disease serum	20
46. Anti-smallpox serum	21
47. Anti-rubella serum	21
48. Gas-gangrene antitoxin (oedematiens)	22
49. Anti-staphylococcal P-V leucocidin serum	22
50. Anti-Rh ₀ (anti-D) incomplete blood-typing serum	22
51. Anti-Rh ₀ (anti-D) complete blood-typing serum	23
52. Other blood-typing sera	23
53. Long-acting thyroid stimulator	24
54. Other human auto-immune antibodies	24
55. <i>Naja</i> antivenin	24
56. Other antivenins	24
57. Cholera agglutinating sera	24
58. Anti-canine-distemper serum	25
59. Anti-canine-hepatitis serum	25
MISCELLANEOUS	
60. Interferon	25
BIOLOGICAL REFERENCE REAGENTS	
61. Anti-leptospira sera	25
62. Enterovirus antisera	27

	Page
63. Adenovirus antisera	28
64. Respiratory virus and <i>Mycoplasma pneumoniae</i> antisera	28

REQUIREMENTS FOR BIOLOGICAL SUBSTANCES

65. Requirements for anthrax spore vaccine (live—for veterinary use). . .	28
66. Requirements for human immunoglobulin	29
67. Requirements for procaine benzylpenicillin in oil with aluminium monostearate	29
68. Requirements for typhoid vaccine	29
69. Requirements for other biological substances	30

ANNEXES

Annex 1. Requirements for anthrax spore vaccine (live—for veterinary use) (Requirements for biological substances No. 13)	31
Annex 2. Requirements for human immunoglobulin (Requirements for biological substances No. 14)	41
Annex 3. Requirements for procaine benzylpenicillin in oil with aluminium monostearate (Requirements for biological substances No. 9), revisions adopted 1966	57
Annex 4. Requirements for typhoid vaccine (Requirements for biological substances No. 15)	61
Annex 5. Requirements for biological substances (general description and list of published documents)	76
Annex 6. International biological standards and international biological reference preparations, 1967	79
Annex 7. International biological reference reagents.	108
Annex 8. Proposed international biological standards, international biological reference preparations and international biological reference reagents	114
Annex 9. Discontinued international biological standards	118

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 28 November - 3 December 1966

*Members : **

- Dr D. R. Bangham, Director, Division of Biological Standards, National Institute for Medical Research, Mill Hill, London, England
- Dr L. Greenberg, Chief, Biologics Control Laboratory, Department of National Health and Welfare, Laboratory of Hygiene, Ottawa, Ontario, Canada (*Rapporteur*)
- Dr E. N. Melikova, Chief, Unit of Bacterial Vaccines, L. A. Tarasevič State Control Institute for Medico-Biological Preparations, Moscow, USSR
- Dr R. Murray, Director, Division of Biological Standards, National Institutes of Health, Public Health Service, Bethesda, Md., USA (*Chairman*)
- Dr G. Penso, Chief, Laboratory of Microbiology, Istituto Superiore di Sanità, Rome, Italy
- Dr J. D. van Ramshorst, Chief, Department of Biological Standardization, Rijks Instituut voor de Volksgezondheid, Utrecht, Netherlands
- Dr M. Rouchdi, Director-General, Public Health Laboratories, Cairo, UAR
- Dr J. B. Shrivastav, Director, National Institute of Communicable Diseases, New Delhi, India (*Vice-Chairman*)
- Dr J. Spaun, Deputy Director, Department of Biological Standards, Statens Serum-institut, Copenhagen, Denmark
- Dr W. W. Wright, Deputy Director, Division of Antibiotics and Insulin Certification, Food and Drug Administration, Washington, D.C., USA

Representative of the Food and Agriculture Organization of the United Nations :

- Mr I. Davidson, Senior Research Officer, Central Veterinary Laboratory, Weybridge, Surrey, England

Secretariat :

- Mr E. C. Hulse, Director, Department of Biological Standards, Central Veterinary Laboratory, Weybridge, Surrey, England (*Consultant*)
- Dr A. N. Klimov, Director, Division of Biomedical Sciences, WHO, Geneva
- Dr P. Krag, Director, Department of Biological Standards, Statens Serum-institut, Copenhagen, Denmark (*Consultant*)
- Mr J. W. Lightbown, Division of Biological Standards, National Institute for Medical Research, Mill Hill, London, England (*Consultant*)
- Dr A. S. Outschoorn, Chief Medical Officer, Biological Standardization, WHO, Geneva (*Secretary*)

* Unable to attend : Dr A. Sohier, Director, Section of Virology, National Public Health Laboratory, Lyons, France.

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Nineteenth Report

The WHO Expert Committee on Biological Standardization met in Geneva from 28 November to 3 December 1966.

Dr P. Dorolle, Deputy Director-General, on behalf of the Director-General, welcomed the members of the Committee. He also welcomed the representative of the Food and Agriculture Organization of the United Nations.

Recalling the development of biological standardization, the Deputy Director-General stated that most of the members of the Committee had had long association with it and could be depended upon to maintain the high standard expected of the Committee. Reviewing briefly the agenda before the Committee, he said that over the years many international biological standards, reference preparations and reference reagents had been established, but more were needed. He cited some of the more important substances for which standards were to be considered. He also referred to the increasing responsibility of the Committee for adopting the sets of international requirements for biological substances.

GENERAL

The Committee considered some aspects of the general problems that exist when valid assays of certain biological preparations cannot be made with particular international standards because of differences in constitution between the standards and the test preparations, which may or may not be related to their biological activity. Examples of materials that present problems of this kind are : adsorbed and non-adsorbed vaccines, the tuberculins, snake antivenins (against the same species), families of antibiotics and hormones of human and animal origin. This last example is of concern in relation to the assay of certain hormones in human material by radio-immunoassay procedures. These recently introduced techniques have aroused much interest on account of their greater sensitivity and precision as compared to conventional assay methods. In many instances, existing international standards prepared from animal materials, which may be used satisfactorily in conventional bio-assays, cannot be used for assays of human material by radio-immunoassay techniques ; for this purpose, reference

material, generally of human origin, has to be provided. In view of the difficulties so often encountered in characterizing human reference material in terms of the relevant international standard, the Committee asked the WHO Secretariat to collect information that would enable a decision to be made on the general principles to be followed and the measures to be adopted in establishing international standards for particular biological substances of importance in medicine and in selecting suitable material.

PHARMACOLOGICAL

ANTIBIOTICS

1. Gramicidin

The Committee noted¹ that the collaborative assay of the proposed international reference preparation of gramicidin had been completed and that in accordance with the authorization in its seventeenth report,² the National Institute for Medical Research, London, had established the International Reference Preparation of Gramicidin and, with the agreement of the participants, had defined the International Unit for Gramicidin as the activity contained in 0.001 mg of the International Reference Preparation of Gramicidin.

2. Dihydrostreptomycin

The Committee noted³ that the collaborative assay of the proposed second international standard for dihydrostreptomycin had been completed and that in accordance with the authorization in its sixteenth report,⁴ the National Institute for Medical Research, London, had established the second International Standard for Dihydrostreptomycin in replacement of the first international standard and, with the agreement of the participants, had defined the International Unit for Dihydrostreptomycin as the activity contained in 0.001219 mg of the International Standard for Dihydrostreptomycin.

3. Viomycin

The Committee noted⁵ that the collaborative assay of the proposed international standard for viomycin had been completed. The Committee

¹ Unpublished working document WHO/BS/858.

² *Wld Hlth Org. techn. Rep. Ser.*, 1964, 293.

³ Unpublished working document WHO/BS/829 and *Bull. Wld Hlth Org.*, 1966, 34, 429.

⁴ *Wld Hlth Org. techn. Rep. Ser.*, 1964, 274.

⁵ Unpublished working document WHO/BS/850.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30866

